Effects of hyperosmolar glucose, prostaglandin-F2 alpha and 15-methyl-prostaglandin-F2 alpha on human placental cells in vitro. 1995

G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
Department of Obstetrics and Gynecology, University of Göteborg, Sahlgrenska Hospital, Sweden.

The objective of this study was to assess the ability of certain drugs, used for local injection therapy of ectopic pregnancy, to suppress the activities of cultured human placental cells. Placental cells from legal first trimester abortions were prepared by collagenase treatment and density gradient centrifugation. The cells were exposed to hyperosmolar glucose (500 mg/ml), 15-methyl-prostaglandin-F2 alpha (15-m-PGF2 alpha; 10(-7) to 10(-3) mol/l) and prostaglandin-F2 alpha (PGF2 alpha; 10(-5) to 5 x 10(-3) mol/l) for 30 min on days 2-4 after seeding. The effects on the secretion of human chorionic gonadotrophin (HCG) and progesterone, as well as on the protein content per culture well, were measured. Hyperosmolar glucose was the most effective drug and caused a marked decrease of the protein content in the culture wells and a reduction of progesterone secretion. Of the two prostaglandins, only 15-m-PGF2 alpha affected the viability of the cells and reduced the protein content of the wells. The clinical effectiveness of the two groups of drugs seems to be similar but certain in-vitro effects are different. Thus in vivo they may act on different target tissues. Against this background, the combination of hyperosmolar glucose and prostaglandins might be an interesting approach for local injection therapy for tubal pregnancy.

UI MeSH Term Description Entries
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D002260 Carboprost A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY. 15-Methylprostaglandin F2alpha,15(S)-15-Methyl PGF2alpha,15 Methylprostaglandin F2alpha
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
June 1994, Prostaglandins, leukotrienes, and essential fatty acids,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
January 1991, Yao xue xue bao = Acta pharmaceutica Sinica,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
October 1986, Sheng li xue bao : [Acta physiologica Sinica],
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
September 1990, Lancet (London, England),
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
March 1984, Yao xue xue bao = Acta pharmaceutica Sinica,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
November 1991, Ugeskrift for laeger,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
February 1980, Chinese medical journal,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
May 1980, European journal of gynaecological oncology,
G Bengtsson, and A Wallin, and P Sjöblom, and B Lindblom
January 1978, Fertility and sterility,
Copied contents to your clipboard!